Banner

Ocular bacterial treatment in development

Article

Alameda, CA-InSite Vision Inc. and Bausch & Lomb have signed a licensing agree-ment to develop InSite's product ISV-403 for the treatment of ocular bacterial infections.

Related Content

The ins and outs of treating ‘financial cataracts’

April 26th 2023

Planning for financial safety in uncertain times

October 31st 2020

Are there alternative opportunities in volatile markets?

October 28th 2022

The sword and shield of investing

May 20th 2022

Ten steps for planning your retirement cash flow

April 13th 2022

Webinar replay: Channeling the Beatles in a financial market outlook – come together

April 12th 2022

The ins and outs of treating ‘financial cataracts’

April 26th 2023

Planning for financial safety in uncertain times

October 31st 2020

Are there alternative opportunities in volatile markets?

October 28th 2022

The sword and shield of investing

May 20th 2022

Ten steps for planning your retirement cash flow

April 13th 2022

Webinar replay: Channeling the Beatles in a financial market outlook – come together

April 12th 2022

The ins and outs of treating ‘financial cataracts’

April 26th 2023

Planning for financial safety in uncertain times

October 31st 2020

Are there alternative opportunities in volatile markets?

October 28th 2022

The sword and shield of investing

May 20th 2022

Ten steps for planning your retirement cash flow

April 13th 2022

Webinar replay: Channeling the Beatles in a financial market outlook – come together

April 12th 2022
© 2023 MJH Life Sciences

All rights reserved.